Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Chronic Lymphocytic Leukemia
Type
Interventional
Phase
Phase 4
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by: High-throughput ex vivo drug assay (2D platforms) Global transcriptome analysis by RNA sequencing Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80, CD86, HLA-DR, ...

LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by: High-throughput ex vivo drug assay (2D platforms) Global transcriptome analysis by RNA sequencing Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80, CD86, HLA-DR, CD38, CD49d, CXCR4; Phospho-flow assays, to assess the phosphorylation state of proteins involved in BCR signaling transduction, e.g. AKT and ERK; Western blot of nuclear lysates and cytoplasmic protein fractions to validate the expression of relevant genes Targeted deep-sequencing by a previously validated panel Minimal residual disease evaluation will be performed by: 6-color flow cytometry NGS CfDNA will be analysed by targeted NGS. The following features will be evaluated by tailored ultrasound: Superficial nodal sites (linear probe 7.5 MHz): Site Size: long and short diameter (sensitivity <5 mm) Shape Border echo-structure of the cortex; assessment of possible intranodal reticulation Echogenic description of the hilum: presence, absence and irregular echo-morphology Optional parameters: Doppler evaluation: vascular distribution, vascular resistance Contrast enhanced ultrasound (CEUS): 7.5 MHz linear probe (optional);Quantitative assessment with dedicated software (wash-in and wash-out curves): optional Deep nodal sites (probe 3.5-5 MHz): Site Presence/absence of deep lymphoadenopathies Size (sensitivity <5 mm) Echo-structure of the cortex (only if superficial, e.g. external iliac LN) Optional parameters: Vascular pattern by: color doppler, two-dimensional power doppler and MicroV (only if superficial, e.g. external iliac LN) Contrast enhanced ultrasound (CEUS) (optional): vascular pattern present vs absent, intensity Spleen: Size (dedicated software to more precisely define the bipolar diameter) : in cm Cross sectional area in cm2 Optional parameters: Splenic artery resistive index Portal vein flow (forward or non-forward portal flow): Vmax ("maximum velocity expressed in cm" and "mean Velocity expressed in cm") Splenic stiffness (with Fibroscan or point share wave or share wave 2D) expressed in kPa Liver: Size Echo-structure Optional parameters: Portal vein flow parameters Liver artery resistive index Liver stiffness expressed in kPa

Tracking Information

NCT #
NCT04790045
Collaborators
Not Provided
Investigators
Not Provided